GlassScriptPhysician profile
Edward W Hearn
NPI 1902984651
$4,250.21
in general payments reported to CMS, 2019-2025
19 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,862 · 2020: $312 · 2021: $1,103 · 2022: $119 · 2023: $370 · 2024: $360 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $528.46 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $489.44 | 2019-2024 | Imfinzi |
| Celgene Corporation | $373.21 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $356.89 | 2019-2023 | Reblozyl |
| Beigene USA, INC. | $352.29 | 2021-2024 | Brukinsa |
| Genentech USA, INC. | $259.92 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $245.94 | 2019 | |
| Daiichi Sankyo INC. | $227.73 | 2021 | |
| Pfizer INC. | $214.46 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $191.02 | 2019 | |
| Beone Medicines USA, INC. | $124.77 | 2025 | Brukinsa |
| Epizyme, INC. | $123.50 | 2021 | |
| Janssen Biotech, INC. | $122.95 | 2023 | Carvykti, Tecvayli, Darzalex |
| Glaxosmithkline, LLC. | $119.82 | 2020 | |
| Heron Therapeutics, INC. | $119.17 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $108.20 | 2019 | |
| Alexion Pharmaceuticals, INC. | $100.34 | 2019 | |
| Portola Pharmaceuticals, LLC | $99.57 | 2020 | |
| Amgen INC. | $92.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Hearn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.